摘要
目的研究不同剂量瑞舒伐他汀治疗对急性冠状动脉综合征(ACS)患者体内炎性因子水平的影响。方法选取2018年1月—2019年1月我院收治的ACS患者98例为研究对象,按用药剂量不同分为观察组和对照组,每组49例。对照组采用常规剂量瑞舒伐他汀(10 mg/d),观察组给予大剂量瑞舒伐他汀(20 mg/d),2组均持续服用12周。观察2组治疗前后肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)、超敏C反应蛋白(hs-CRP)、血管内皮生长因子(VEGF)、内皮素-1(ET-1)及一氧化氮(NO)、甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平。统计2组不良反应发生情况。结果2组治疗后TNF-α、IL-6、hs-CRP、ET-1、TG、TC、LDL-C水平显著低于治疗前,且观察组上述指标显著低于对照组(P<0.05)。2组治疗后VEGF、NO、HDL-C水平显著高于治疗前,且观察组显著高于对照组(P<0.05)。2组不良反应总发生率比较差异无统计学意义(P>0.05)。结论大剂量与常规剂量瑞舒伐他安全性相似,但前者对ACS患者血清炎性因子、血管内皮功能、血脂的改善效果更好。
Objective To explore the effect of different doses of Rosuvastatin on the level of inflammatory factors in patients with acute coronary syndrome(ACS).Methods Ninety-eight ACS patients admitted to our hospital from January 2018 to January 2019 were selected as the research subjects,and were divided into the observation group and the control group according to the different dosage,with 49 cases in each group.The control group was given a conventional dose of Rosuvastatin(10 mg/d),while the observation group was given a large dose of Rosuvastatin(20 mg/d).Both groups were treated for 12 consecutive weeks.The levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),high-sensitivity C-reactive protein(hs-CRP),vascular endothelial growth factor(VEGF),endothelin-1(ET-1),nitric oxide(NO),triglycerides(TG),total cholesterol(TC),high-density lipoprotein cholesterol(HDL-C)and low-density lipoprotein cholestero(LDL-C)in both groups were observed before and after treatment.The adverse reactions of the two groups were recorded.Results The levels of TNF-α,IL-6,hs-CRP,ET-1,TG,TC and LDL-C in the two groups were significantly lower than those before treatment,which were significantly lower in the observation group than in the control group(P<0.05).After treatment,the levels of VEGF,NO and HDL-C in the two groups were significantly higher than those before treatment,and those in the observation group were significantly higher than those in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion High dose and conventional dose of Rosuvastar are similar in safety,but the former has a better effect on the improvement of serum inflammatory factors,vascular endothelial function and blood lipid in patients with ACS.
作者
贾媛媛
赵殿儒
田田
马桂英
杨震
罗建平
高丽萍
JIA Yuan-yuan;ZHAO Dian-ru;TIAN Tian;MA Gui-ying;YANG Zhen;LUO Jian-ping;GAO Li-ping(Department of Cardiovascular Medicine,People's Hospital of Cangzhou,Cangzhou,Hebei 061001,China;Department of Cardiovascular Medicine,General Hospital of Beijing Jingmei Group,Beijing 102300,China;Department of Paediatrics,County Hospital of Yuanshi,Yuanshi,Hebei 051130,China)
出处
《解放军医药杂志》
CAS
2020年第8期32-35,共4页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
河北省卫生厅科研基金项目(20181135)
沧州市重点研发计划指导项目(172302058)。
作者简介
通讯作者:田田,E-mail:nancy_sweet@126.com。
